SUDARSHAN

- Sudarshan Pharma Industries Ltd announced that its Board of Directors approved raising funds up to Rs. 72 crores via issuance and allotment of convertible warrants. - Warrants will be issued on a preferential basis to promoters Mr. Hemal Mehta and Sachin Mehta. - Each warrant is convertible into 1 equity share of face value Re. 1/-. - The proposal is subject to statutory/regulatory approvals and shareholder approval at an Extraordinary General Meeting (EGM).

- The Board of Directors of Sudarshan Pharma Industries Ltd approved raising funds through the issue and allotment of up to 72,00,00,000 warrants on a preferential basis to promoters Mr. Hemal Mehta and Mr. Sachin Mehta. - Each warrant is convertible into 1 equity share of face value Re. 1/- at a price determined as per SEBI ICDR Regulations. - The proposal is subject to regulatory, statutory, and shareholder approvals at an upcoming Extraordinary General Meeting (EGM).

Q2 FY27 Consolidated Revenue ₹216.97Cr vs ₹168.87Cr (▲28% YoY) EBITDA ₹20.58Cr vs ₹10.22Cr (▲101% YoY) PAT ₹7.78Cr vs ₹3.87Cr (▲101% YoY) EBITDA Margin 9.5% vs 6.1% (▲340bps)

- Board meeting scheduled on Thursday, October 29, 2026. - To consider and approve Unaudited Standalone and Consolidated Financial Results for the quarter and half-year ended September 30, 2026. - To consider and approve a proposal for fund raising through equity, convertible securities, warrants, or debt instruments via Private Placement, Preferential Issue, or QIP.

- Sudarshan Pharma Industries Limited has received approval from NSE for migration from the SME Platform of BSE to the Capital Market Segment (Main Board) of NSE. - The equity shares of the company will be listed and admitted to dealings on NSE with effect from October 27, 2026. - Trading symbol will remain 'SUDARSHAN' under the 'EQ' series with 25,44,70,600 fully paid-up equity shares of Re. 1/- each.